Ya Quig there was some money to be made on the other races for sure.
Love Derby Day. I tossed in a simple Superfecta ticket with AP on top and the usual suspects below. $634 not bad but pretty low for a derby SF. I'll take it though. Could have a legitimate shot at the Triple Crown. That will be fun to see. Now lets go GEM!!
Though its one of the biggest races its too hard to get an angle on it. Easier to play the maiden races for me. with that said I still took a shot with Frosted. Next year.
Maddi, been watching the bias and the CA horses haven't been winning. That said I never bet the favorites so I'll take the 8 (while Dortmund has been running out West, he's won at CD), 15 and 19 on top - wheeling a host of horses in the number 2 and 3 spot. Good luck!!
They have been granted orphan drug status for (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one for the treatment of Hodgkin lymphoma. I wonder why no PR yet.
I'm with jacosa. GILD will almost certainly provide some kind of data for their momelotinib trials underway. We still have a couple years but the window is closing for our monopoly in JAK/MF, so I'm more anxious than usual going into june/asco (which actually starts in may this year). Take a look at how many MF trials they're running right now for momelotinib, there's a ton
Heading to Oaks now Maddi - was at the backside yesterday morning. Dortmumd is a monster! I'll do my handicapping tonight and check back. Just a great weekend all around. Enjoy and I'll post my pick for ya if I survive the Oaks!!
Every little bit helps Quig. That's three analyst upgrades thus far. Hoping we regroup and continue are momentum...a pause and refresh from time to time is healthy! Have a great weekend everyone - Oaks, Derby, Big Fight Night - what a weekend!!
agreed went up 20% in 10 days....now down 10% in 5 days.... time to go back up to new highs. ASCO abstract release in a couple weeks.... I think we might be in for a surprise
That would be sweet. I've never placed a before market trade so I hope it doesn't spike before I grab some
I still make it a Q/Q sales increase corresponding to 38% annually. That has to be discounted for the inventory rebuild, but you can plausibly predict acceleration in PV (we're only barely starting to see the effect of actual selling into that market, and analysts ought to realize that) so it should be fairly representative.
Anyway, if we're still focused on MPNs a year from now we will have already lost.
That hasn't changed. Key Drug to market and generating revenue. The pipeline is still rich. Yes they're spending R&D to move the strong pipeline forward. All this does is make someone lick their chops more in my opinion. This puke purge as Sooz mentioned will end and where do you think the money will flow? Just sayin - Still a GEM!
quarter on quarter sales..... i think that is why we sold off today, with the rest of bios. i don't make much of it on a one quarter basis, but if uptake is not better over the next couple/few quarters i will possibly change my mind. overall, i still content to maintain my position and keep adding on and drop into the lower 90's should that happen. my personal feeling is that we are close to a low on the overall sector puke and i am buying fidelity select biotech fund today.
I'd like to keep the other item for what people thought was notable IN the CC. So I won't comment myself on the reaction in that item.
I can understand the price drop. Even the general analyst predictions were awfully ambitious, and the whispers seem to have gotten ridiculous.
There's probably a lot of concern out there that Incyte is following a classic road which leads small, innovative companies to failure. "So many attractive projects; they'll all make money some day, so let's chase them all!!"
But Incyte is restraining itself, keeping the clinical program growing, but with restraint. Still, with the visible pipeline growing rapidly, new financing is likely to be needed. That's an uncertainty, and uncertainty costs the stock price.
And also, this was the last opportunity for a positive surprise before ASCO, and there was none. I've said before that I expect ASCO to be negative for the stock price because investors will be reminded that Jakafi has potential competitors.
I'm still bullish as all getout, but I can sympathize with those who aren't. [~30% CAGR on stock price coming over several years--try to get that from a mutual fund]